Molecular mechanisms and phenotypic variation in RYR1-related congenital myopathies
- PMID: 17483490
- DOI: 10.1093/brain/awm096
Molecular mechanisms and phenotypic variation in RYR1-related congenital myopathies
Abstract
Dominant mutations in the skeletal muscle ryanodine receptor (RYR1) gene are well-recognized causes of both malignant hyperthermia susceptibility (MHS) and central core disease (CCD). More recently, recessive RYR1 mutations have been described in few congenital myopathy patients with variable pathology, including multi-minicores. Although a clinical overlap between patients with dominant and recessive RYR1 mutations exists, in most cases with recessive mutations the pattern of muscle weakness is remarkably different from that observed in dominant CCD. In order to characterize the spectrum of congenital myopathies associated with RYR1 mutations, we have investigated a cohort of 44 patients from 28 families with clinical and/or histopathological features suggestive of RYR1 involvement. We have identified 25 RYR1 mutations, 9 of them novel, including 12 dominant and 13 recessive mutations. With only one exception, dominant mutations were associated with a CCD phenotype, prominent cores and predominantly occurred in the RYR1 C-terminal exons 101 and 102. In contrast, the 13 recessive RYR1 mutations were distributed evenly along the entire RYR1 gene and were associated with a wide range of clinico-pathological phenotypes. Protein expression studies in nine cases suggested a correlation between specific mutations, RyR1 protein levels and resulting phenotype: in particular, whilst patients with dominant or recessive mutations associated with typical CCD phenotypes appeared to have normal RyR1 expression, individuals with more generalized weakness, multi-minicores and external ophthalmoplegia had a pronounced depletion of the RyR1 protein. The phenomenon of protein depletion was observed in some patients compound heterozygous for recessive mutations at the genomic level and silenced another allele in skeletal muscle, providing additional information on the mechanism of disease in these patients. Our data represent the most extensive study of RYR1-related myopathies and indicate complex genotype-phenotype correlations associated with mutations differentially affecting assembly and function of the RyR1 calcium release channel.
Similar articles
-
Minicore myopathy with ophthalmoplegia caused by mutations in the ryanodine receptor type 1 gene.Neurology. 2005 Dec 27;65(12):1930-5. doi: 10.1212/01.wnl.0000188870.37076.f2. Neurology. 2005. PMID: 16380615
-
Magnetic resonance imaging of muscle in congenital myopathies associated with RYR1 mutations.Neuromuscul Disord. 2004 Dec;14(12):785-90. doi: 10.1016/j.nmd.2004.08.006. Neuromuscul Disord. 2004. PMID: 15564033
-
Centronuclear myopathy due to a de novo dominant mutation in the skeletal muscle ryanodine receptor (RYR1) gene.Neuromuscul Disord. 2007 Apr;17(4):338-45. doi: 10.1016/j.nmd.2007.01.016. Epub 2007 Mar 21. Neuromuscul Disord. 2007. PMID: 17376685
-
[Congenital myopathies].Rev Neurol. 2003 Oct 16-31;37(8):779-86. Rev Neurol. 2003. PMID: 14593641 Review. Spanish.
-
Ryanodine receptor mutations in malignant hyperthermia and central core disease.Hum Mutat. 2000;15(5):410-7. doi: 10.1002/(SICI)1098-1004(200005)15:5<410::AID-HUMU2>3.0.CO;2-D. Hum Mutat. 2000. PMID: 10790202 Review.
Cited by
-
Oxidative stress and successful antioxidant treatment in models of RYR1-related myopathy.Brain. 2012 Apr;135(Pt 4):1115-27. doi: 10.1093/brain/aws036. Epub 2012 Mar 14. Brain. 2012. PMID: 22418739 Free PMC article.
-
Ryanodine Receptor 1-Related Myopathies: Diagnostic and Therapeutic Approaches.Neurotherapeutics. 2018 Oct;15(4):885-899. doi: 10.1007/s13311-018-00677-1. Neurotherapeutics. 2018. PMID: 30406384 Free PMC article. Review.
-
Genetic risk for malignant hyperthermia in non-anesthesia-induced myopathies.Mol Genet Metab. 2011 Sep-Oct;104(1-2):167-73. doi: 10.1016/j.ymgme.2011.07.001. Epub 2011 Jul 12. Mol Genet Metab. 2011. PMID: 21795085 Free PMC article.
-
Novel excitation-contraction uncoupled RYR1 mutations in patients with central core disease.Neuromuscul Disord. 2013 Feb;23(2):120-32. doi: 10.1016/j.nmd.2012.08.007. Epub 2012 Nov 24. Neuromuscul Disord. 2013. PMID: 23183335 Free PMC article.
-
Rycal S48168 (ARM210) for RYR1-related myopathies: a phase one, open-label, dose-escalation trial.EClinicalMedicine. 2024 Jan 25;68:102433. doi: 10.1016/j.eclinm.2024.102433. eCollection 2024 Feb. EClinicalMedicine. 2024. PMID: 38318125 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases

